Literature DB >> 21819253

Long-term outcome of transobturator tension-free vaginal tape: efficacy and risk factors for surgical failure.

Asnat Groutz1, Gila Rosen, Ronen Gold, Joseph B Lessing, David Gordon.   

Abstract

PURPOSE: To assess the 5-year efficacy of the inside-out transobturator tension-free vaginal tape (TVT-O) for the treatment of stress urinary incontinence (SUI) and to explore possible predictors for long-term failure.
METHODS: Sixty-five consecutive patients who underwent TVT-O were prospectively enrolled. Patients who required concomitant anterior or apical pelvic organ prolapse repair or both and those with urodynamic occult SUI were excluded. Postoperatively, patients were scheduled for evaluation at 1, 3, 6, and 12 months and annually thereafter. Surgical failure was defined as positive stress test, daily episodes of SUI, and negative global satisfaction. Preoperative and interim clinical and urodynamic predictors for long-term failure were analyzed from a computerized database.
RESULTS: Sixty-one patients (mean age at surgery 56.6±10.2 years) completed 5 years of follow-up. Of these, 11 (18%) patients were classified as surgical failure, 5 (8%) as improved, and 45 (74%) as cured. Any SUI (100% vs. 10%, p=0.001), daily SUI (100% vs. 0%, p=0.001), overactive bladder (OAB) (100% vs. 48%, p=0.001), and the use of antimuscarinic drugs (64% vs. 26%, p=0.03) were found to be significantly more common among failure cases. Preoperative detrusor overactivity (odds ratio [OR] 7.6, 95% confidence interval [CI] 1.7-32.9), interim 1-year OAB (OR 20.5, 95% CI 1.9-215.4), and interim 1-year SUI (OR 26.4, 95% CI 1.5-475.2) were found to be significant independent risk factors for long-term surgical failure.
CONCLUSIONS: An 18% rate of surgical failure was observed 5 years after TVT-O. Larger studies with longer follow-up periods may facilitate the identification of risk factors for failure and, thus, enable better preoperative consultation.

Entities:  

Mesh:

Year:  2011        PMID: 21819253     DOI: 10.1089/jwh.2011.2854

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  6 in total

1.  Long-term outcome of transobturator suburethral tape procedure for treatment of female stress urinary incontinence.

Authors:  Sayed M El-Eweedy; Ahmed F Abd El-Rahim; Mohamed A Abd-Alkhalek; Ashraf H Abdellatif; Ahmed S Anwer
Journal:  Urol Ann       Date:  2014-07

2.  Management of recurrent stress urinary incontinence after failed midurethral sling: tape tightening or repeat sling?

Authors:  Ji-Yeon Han; Kyung Hyun Moon; Chang Myeon Park; Myung-Soo Choo
Journal:  Int Urogynecol J       Date:  2012-04-14       Impact factor: 2.894

Review 3.  Safety considerations for synthetic sling surgery.

Authors:  Jerry G Blaivas; Rajveer S Purohit; Matthew S Benedon; Gabriel Mekel; Michael Stern; Mubashir Billah; Kola Olugbade; Robert Bendavid; Vladimir Iakovlev
Journal:  Nat Rev Urol       Date:  2015-08-18       Impact factor: 14.432

4.  Seven years of objective and subjective outcomes of transobturator (TVT-O) vaginal tape: why do tapes fail?

Authors:  Stavros Athanasiou; Themos Grigoriadis; Dimitrios Zacharakis; Nikolaos Skampardonis; Dionysia Lourantou; Aris Antsaklis
Journal:  Int Urogynecol J       Date:  2013-07-27       Impact factor: 2.894

Review 5.  Clinical risk factors and urodynamic predictors prior to surgical treatment for stress urinary incontinence: a narrative review.

Authors:  Mette Hornum Bing; Helga Gimbel; Susanne Greisen; Lene Birgitte Paulsen; Helle Christina Soerensen; Gunnar Lose
Journal:  Int Urogynecol J       Date:  2014-09-24       Impact factor: 2.894

6.  Randomized controlled trial comparing TVT-O and TVT-S for the treatment of stress urinary incontinence: 2-year results.

Authors:  Ana Maria H M Bianchi-Ferraro; Zsuzsanna I K Jarmy-DiBella; Rodrigo de Aquino Castro; Maria Augusta T Bortolini; Marair G F Sartori; Manoel J B C Girão
Journal:  Int Urogynecol J       Date:  2014-03-19       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.